Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B3i Trial: Brigatinib for Brain Metastases From ALK+ Lung Cancer
NCT04634110Phase 2Terminated
- Sponsor
- University of Colorado Denver
- Start
- Nov 2020
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brigatinib in non-small cell lung cancer (NSCLC), brain metastases, sponsored by University of Colorado Denver. Started Nov 2020; status: terminated.
02
Drugs
brigatinib
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on NCT04634110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04634110.